Why Medical Device Sales Cycles Keep Stretching — And What to Do About It | NPLUS Global

If your average deal used to close in four months and now takes nine, you're not imagining it and you're not doing something obviously wrong. Health systems have added layers — value analysis committees, IT security review, GPO contract checks, multi-site sign-off — faster than most vendors have adjusted their pipeline math. The result isn't just longer cycles; it's cycles that look stalled when they're actually just moving through stages nobody mapped for.

This isn't a pitch for shortcuts. Some of these gates exist for good reasons (cybersecurity review on a connected infusion pump should take time). The point is to stop treating every delay as a red flag or a rep problem, and start building process around the delays that are now structural. Below is a checklist broken into the four points where deals actually stretch — not "consider your goals," but specific things to check, ask, or document.

Before You Prioritize the Account

• Pull board minutes or public budget documents where available. Hospital systems often publish capital approval summaries; they'll tell you how spending decisions actually get made, not how the sales deck assumes they get made.
• Ask how big the Value Analysis Committee is and how often it meets. A VAC with eight-plus voting members meeting quarterly is not a "quick win" account, no matter how enthusiastic your clinical champion sounds.
• Flag connected devices for IT security review immediately. If the product touches the network, transmits data, or integrates with the EHR, assume a separate security assessment track exists — and that it runs on its own timeline, independent of clinical enthusiasm.
• Check GPO contract status before quoting price. Off-contract purchases usually trigger an exception process with its own approval chain; on-contract deals skip a step that off-contract deals don't.
• Note how long the clinical champion has held their role. A champion under a year into the job is more likely to leave mid-cycle than one who's been there three years — and when they leave, you often restart.

During Committee Review

• Get the actual submission template the VAC uses, not a generic clinical value dossier. Committees increasingly score submissions against a fixed rubric; guessing at the format wastes a review cycle.
• Build a total cost of ownership sheet that includes disposables, service contracts, and staff training hours — not just unit price. Finance representatives on the committee will ask for this specifically, and not having it ready adds a meeting.
• Track every stakeholder who joins or leaves the deal, by name, with date. Committee turnover resets institutional memory. If you don't log it, you'll re-pitch the same points to the same person twice, or miss that someone new needs briefing.
• Log the specific reason for each delay in writing — not "went well" or "still pending." Over enough deals, the pattern (budget timing, infection control sign-off, legal backlog) tells you which gate is actually the bottleneck, and that's the thing worth fixing.
• Confirm the committee's meeting cadence and build your follow-up calendar to it. Chasing a monthly committee weekly doesn't speed anything up; it just signals you don't know how the process works.

After Verbal Commitment, Before Signature

• Confirm the PO is tied to an already-approved capital budget line, not just a budget conversation that happened. "Verbal yes" and "funded line item" are different stages, and conflating them is where a lot of forecast slippage comes from.
• Get legal and compliance review scheduled on an actual calendar, rather than assuming it happens automatically once clinical sign-off is in. In consolidated systems, legal review is often a separate queue with its own backlog.
• Ask directly whether multi-site rollout requires local approval at each facility, even under one signed IDN-level contract. Some systems sign centrally but implement site-by-site, which means "signed" doesn't mean "shipped" for months.
• Get IT security's data-sharing terms in writing before signature, especially for anything transmitting patient-adjacent data. Verbal assurance from a clinical sponsor doesn't bind the security team.
• Identify who actually holds signing authority. In systems that have merged or consolidated recently, the person who negotiated the deal may not be the person who can sign it — confirm this early, not at the finish line.

After the PO Is Signed

• Schedule biomedical/clinical engineering onboarding separately from staff clinical training. These two groups run on different calendars and different priorities; bundling them into one "onboarding" milestone tends to hide slippage in one or the other.
• Lock service contract renewal terms and dates immediately, not at renewal time. When device support timelines and account renewal timelines drift out of sync, every future cycle with that account gets harder to forecast.
• Set a 90-day check-in with the original clinical champion specifically — not the account generally. This is the window where champion turnover quietly stalls reorders or expansion conversations before anyone notices.
• Feed the real cycle-length data back into account scoring, not the projected timeline from the original deal desk. This is less about any one deal and more about not repeating the same misqualification on the next ten accounts that look similar. Data teams working across healthcare account and contact intelligence — this is the kind of feedback loop NPLUS Global builds for go-to-market teams selling into hospitals and IDNs, because the cycle-length pattern is usually visible before the deal is, if someone's tracking it.
• Map adjacent facilities inside the same IDN before pitching them separately. Internal word about a rollout — good or bad — travels faster within a health system than most reps assume, and pitching a sister facility cold when they've already heard about your onboarding problems is a self-inflicted delay.

None of this shortens a cycle that's structurally long. What it does is stop you from mistaking process for stall, and stop your forecast from assuming last year's timeline still applies. The systems didn't get slower by accident — the gates are real, they're multiplying, and the only real lever left is knowing exactly where they sit before you build a quarter around beating them.